Carcinogenicity of radiofrequency electromagnetic fields

In May, 2011, 30 scientists from 14 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of radiofrequency electromagnetic fields (RF-EMF). These assessments will be published as Volume 102 of the IARC Monographs.¹

Human exposures to RF-EMF (frequency range 30 kHz–300 GHz) can occur from use of personal devices (eg, mobile telephones, cordless phones, Bluetooth, and amateur radios), from occupational sources (eg, high-frequency dielectric and induction heaters, and high-powered pulsed radars), and from environmental sources such as mobile-phone base stations, broadcast antennas, and medical applications. For workers, most exposure to RF-EMF comes from near-field sources, whereas the general population receives the highest exposure from transmitters close to the body, such as handheld devices like mobile telephones. Exposure to high-power sources at work might involve higher cumulative RF energy deposited into the body than exposure to mobile phones, but the local energy deposited in the brain is generally less. Typical exposure to the brain from rooftop or tower-mounted mobile-phone base stations and from TV and radio stations are several orders of magnitude lower than those from global system for mobile communications (GSM) handsets. The average exposure from use of digital enhanced cordless telecommunications (DECT) phones is around five times lower than that measured for GSM phones, and third-generation (3G) phones emit it, on average, about 100 times less RF energy than GSM phones, when signals are strong. Similarly, the average output power of Bluetooth wireless hands-free kits is estimated to be around 100 times lower than that of mobile phones.

EMFs generated by RF sources couple with the body, resulting in induced electric and magnetic fields and associated currents inside tissues. The most important factors that determine the induced fields are the distance of the source from the body and the output power level. Additionally, the efficiency of coupling and resulting field distribution inside the body strongly depend on the frequency, polarisation, and direction of wave incidence on the body, and anatomical features of the exposed person, including height, body-mass index, posture, and dielectric properties of the tissues. Induced fields within the body are highly non-uniform, varying over several orders of magnitude, with local hotspots.

Holding a mobile phone to the ear to make a voice call can result in high specific RF energy absorption-rate (SAR) values in the brain, depending on the design and position of the phone and its antenna in relation to the head, how the phone is held, the anatomy of the head, and the quality of the link between the base station and phone. When used by children, the average RF energy deposition is two times higher in the brain in children and up to ten times higher in the bone marrow of the skull, compared with mobile phone use by adults.² Use of hands-free kits lowers exposure to the brain to below 10% of the exposure from use at the ear, but it might increase exposure to other parts of the body.³

Epidemiological evidence for an association between RF-EMF and cancer comes from cohort, case-control, and time-trend studies. The populations in these studies were exposed to RF-EMF in occupational settings, from sources in the general environment, and from use of wireless (mobile and cordless) telephones, which is the most extensively studied exposure source. One cohort study⁴ and five case-control studies⁵–⁹ were judged by the Working Group to offer potentially useful information regarding associations between use of wireless phones and glioma.

The cohort study include 257 cases of glioma among 420 095 subscribers to two Danish mobile phone companies between 1982 and 1995. Glioma incidence was near the national average for the subscribers. In this study, reliance on subscription to a mobile phone provider, as a surrogate for mobile phone use, could have resulted in considerable misclassification in exposure assessment. Three early case-control studies encompassed a period when mobile phone use was low, users typically had low cumulative exposures, time since first use of a mobile phone was short, and effect estimates were generally imprecise; the Working Group considered these studies less informative. Time-trend analyses did not show an increased rate of brain tumours after the increase in mobile phone use. However, these studies have substantial limitations because most of the analyses examined trends until the early 2000s only. Such analyses are uninformative if excess risk only manifests more than a decade after phone use begins, or if phone use only affects a small proportion of cases—eg, the most heavily exposed, or an subset of brain tumours.

The INTERPHONE study,¹⁰ a multicentre case-control study, is the largest investigation so far of mobile phone use and brain tumours, including glioma, acoustic neuroma, and meningioma. The pooled analysis included 2708 glioma cases and 2972 controls (participation rates 64% and 53%, respectively). Comparing those who ever used mobile phones with those who never did yielded an odds ratio (OR) of 0·81 (95% CI 0·70–0·94). In terms of cumulative call time, ORs were uniformly below or close to unity for all deciles of exposure except the highest decile (>1640 h of use), for which the OR for glioma was 1·40 (95% CI 1·03–1·89). There was suggestion of an increased risk for ipsilateral exposure (on the same
side of the head as the tumour) and for tumours in the temporal lobe, where RF exposure is highest. Associations between glioma and cumulative specific energy absorbed at the tumour location were examined in a subset of 553 cases that had estimated RF doses. The OR for glioma increased with increasing RF dose for exposures 7 years or more before diagnosis, whereas there was no association with estimated dose for exposures less than 7 years before diagnosis.

A Swedish research group did a pooled analysis of two very similar studies of associations between mobile and cordless phone use and glioma, acoustic neuroma, and meningioma. The analysis included 1148 glioma cases (ascertained 1997–2003) and 2438 controls, obtained through cancer and population registries, respectively. Self-administered mailed questionnaires were followed by telephone interviews to obtain information on the exposures and covariates of interest, including use of mobile and cordless phones (response rates 85% and 84%, respectively). Participants who had used a mobile phone for more than 1 year had an OR for glioma of 1.3 (95% CI 1.1–1.6). The OR increased with increasing time since first use and with total call time, reaching 3.2 (2.0–5.1) for more than 2000 h of use. Ipsilateral total call time, reaching 3.2 (2.0–5.1), was associated with ipsilateral mobile phone use.

For meningioma, parotid-gland tumours, leukaemia, lymphoma, and other tumour types, the Working Group found the available evidence insufficient to reach a conclusion on the potential association with mobile phone use. Epidemiological studies of individuals with potential occupational exposure to RF-EMF have investigated brain tumours, leukaemia, lymphoma, and other types of malignancy including uveal melanoma, and cancers of the testis, breast, lung, and skin. The Working Group noted that the studies had methodological limitations and the results were inconsistent. In reviewing studies that addressed the possible association between environmental exposure to RF-EMF and cancer, the Working Group found the available evidence insufficient for any conclusion.

The Working Group concluded that there is “limited evidence in humans” for the carcinogenicity of RF-EMF, based on positive associations between glioma and acoustic neuroma and exposure to RF-EMF from wireless phones. A few members of the Working Group considered the current evidence in humans “inadequate”. In their opinion there was inconsistency between the two case-control studies and a lack of an exposure-response relationship in the INTERPHONE study results; no increase in rates of glioma or acoustic neuroma was seen in the Danish cohort study, and up to now, reported time trends in incidence rates of glioma have not shown a parallel to temporal trends in mobile phone use.

The Working Group reviewed more than 40 studies that assessed the carcinogenicity of RF-EMF in rodents, including seven 2-year cancer bioassays. Exposures included 2450 MHz RF-EMF and various RF-EMF that simulated emissions from mobile phones. None of the chronic bioassays showed an increased incidence of any tumour type in tissues or organs of animals exposed to RF-EMF for 2 years. An increased total number of malignant tumours was found in RF-EMF-exposed animals in one of the seven chronic bioassays.

Increased cancer incidence in exposed animals was noted in two of 12 studies with tumour-prone animals and in one of 18 studies using initiation-promotion protocols. Four of six co-carcinogenesis studies showed increased cancer incidence after exposure to RF-EMF in combination with a known carcinogen; however, the predictive value of this type of study for human cancer is unknown. Overall, the Working Group concluded that there is “limited evidence” in experimental animals for the carcinogenicity of RF-EMF.

The Working Group also reviewed many studies with endpoints relevant to mechanisms of carcinogenesis, including genotoxicity, effects on immune function, gene and protein expression, cell signalling, oxidative stress, and apoptosis. Studies of the possible effects of RF-EMF on the blood-brain barrier and on a variety of effects in the brain were also considered. Although there was evidence of an effect of RF-EMF on some of these endpoints, the Working Group reached the overall conclusion that these results provided only weak mechanistic evidence relevant to RF-EMF-induced cancer in humans.

In view of the limited evidence in humans and in experimental animals, the Working Group classified RF-EMF as “possibly carcinogenic to humans” (Group 2B). This evaluation was supported by a large majority of Working Group members.


International Agency for Research on Cancer, Lyon, France

We declare that we have no conflicts of interest.

Observers

J Elder (Mobile Manufacturers Forum); C Marrant (Léon Bérard Centre, France); R Nuttall (Canadian Cancer Society, Canada); J Rowley (GSM Association, UK); M Swerd (CTIA Wireless Association, USA)

IARC Secretariat


Conflicts of interest

MIE’s spouse owns shares (worth $1350) in Telstra, a telecommunications company in Australia. IBA has received travel and accommodation expenses for presentations on mobile phone use and brain tumours, from various Australian organisations and government groups. EC has received travel and accommodation expenses for presentations organised by France Telecom. RDS has received research support from Fondation Santé et Radiofréquences, and was a paid advisor (>€10000) for the plaintiff’s lawyer on a lawsuit involving radiofrequency exposure. NK is director and board member of the non-profit ITIS foundation that performs exposure assessments for industry and governments, and is president of the board and shareholder of Near Field Technology AG, which controls two companies that develop near-field measurement instruments, simulation software, and medical test equipment. All other Working Group members, specialists, representatives, and secretariat declared no conflicts of interest.
Multiple myeloma

The standard treatment to improve outcomes of patients with multiple myeloma is a combination of high-dose chemotherapy and a novel agent such as lenalidomide. In a phase 3 study led by Antonio Palumbo (Turin, Italy), 402 patients younger than 65 years newly diagnosed with multiple myeloma received four cycles of lenalidomide and low-dose dexamethasone as induction therapy. Patients were then randomly assigned to MPR (melphalan/prednisone/lenalidomide) or MEL200 (high-dose melphalan [200 mg/m²] and autologous stem-cell transplantation). Although response rates were similar in the two groups (20% vs 25%, p=0.49), the primary endpoint, progression-free survival at 2 years, was significantly greater with MEL200 after transplantation (73%) than with MPR (54%, p=0.001). Longer follow-up is needed to assess the effect on overall survival.

Mantle cell lymphoma

The prognosis for patients with mantle cell lymphoma (MCL) is very poor, with a median survival of 3–5 years in elderly patients, because almost all patients relapse after induction therapy. The European MCL trial investigators assessed rituximab as maintenance therapy to reduce relapse. 560 elderly patients (median age 70 years) first received two different chemotherapy regimens combined with rituximab. Patients who responded were randomly assigned to either rituximab or standard interferon alfa. Maintenance therapy was continued until progression or recurrence. At 30 months’ follow-up, interim analyses showed that patients assigned to rituximab maintenance had a longer remission duration than did those on interferon (51 vs 24 months). Patients receiving R-CHOP as induction therapy seemed to have an advantage over rituximab maintenance (3-year overall survival 85% vs 70% with interferon). Rituximab maintenance after R-CHOP induction could become standard treatment for elderly patients with MCL.

Myelofibrosis

There are currently no effective drug therapies for myelofibrosis, and the median survival is less than 6 years. The COMFORT studies assessed the safety and efficacy of ruxolitinib—a JAK1 and JAK2 inhibitor—for treatment of myelofibrosis. COMFORT I, undertaken in the USA, Canada, and Australia, compared ruxolitinib with placebo; COMFORT II, done in Europe, compared ruxolitinib with best available therapy. The results showed that ruxolitinib decreased spleen size (the primary endpoint) and improved symptoms affecting quality of life such as fatigue and weight loss. Ruxolitinib was well tolerated; the most common adverse events were anaemia and low platelet count. Although not a cure, control of symptoms could be a major advance for patients with myelofibrosis.

Hairy cell leukaemia

Hairy cell leukaemia (HCL) is a rare type of leukaemia and HCL-associated mutations are largely unknown. Enrico Tiacci (Perugia, Italy) and colleagues searched for HCL-associated mutations by whole-genome sequencing of leukaemic and matched normal mononuclear cells from a patient with HCL. Of five missense somatic clonal mutations confirmed, the oncogenic BRAF V600E mutation was identified and was further investigated. BRAF was mutated in all 46 HCL patients tested; none of the 193 patients with peripheral B-cell lymphoma (other than HCL) that were tested carried the BRAF V600E mutation. Patients with HCL could benefit from previous work on BRAF and BRAF inhibitors for diagnosis and targeted therapy.

Audrey Ceschia